Myriad Genetics Stock Shares Owned By Insiders
| MYGN Stock | USD 23.26 0.10 0.43% |
Myriad Genetics fundamentals help investors to digest information that contributes to Myriad Genetics' financial success or failures. It also enables traders to predict the movement of Myriad Stock. The fundamental analysis module provides a way to measure Myriad Genetics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Myriad Genetics stock.
Myriad | Shares Owned By Insiders |
Myriad Genetics Company Shares Owned By Insiders Analysis
Myriad Genetics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Myriad Genetics Shares Owned By Insiders | 2.09 % |
Most of Myriad Genetics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Myriad Genetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Myriad Shares Owned By Insiders Driver Correlations
Understanding the fundamental principles of building solid financial models for Myriad Genetics is extremely important. It helps to project a fair market value of Myriad Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since Myriad Genetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Myriad Genetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Myriad Genetics' interrelated accounts and indicators.
Click cells to compare fundamentals
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 2.086999999999999% of Myriad Genetics are shares owned by insiders. This is 86.25% lower than that of the Biotechnology sector and 86.43% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 79.32% higher than that of the company.
Myriad Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Myriad Genetics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Myriad Genetics could also be used in its relative valuation, which is a method of valuing Myriad Genetics by comparing valuation metrics of similar companies.Myriad Genetics is currently under evaluation in shares owned by insiders category among related companies.
Myriad Genetics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Myriad Genetics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Myriad Genetics' managers, analysts, and investors.Environmental | Governance | Social |
Myriad Fundamentals
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.066 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.14) % | ||||
| Current Valuation | 2.14 B | ||||
| Shares Outstanding | 90.51 M | ||||
| Shares Owned By Insiders | 2.09 % | ||||
| Shares Owned By Institutions | 97.91 % | ||||
| Number Of Shares Shorted | 5.1 M | ||||
| Price To Earning | 31.95 X | ||||
| Price To Book | 2.24 X | ||||
| Price To Sales | 2.33 X | ||||
| Revenue | 678.4 M | ||||
| Gross Profit | 476.4 M | ||||
| EBITDA | (67.8 M) | ||||
| Net Income | (112 M) | ||||
| Cash And Equivalents | 205.1 M | ||||
| Cash Per Share | 2.54 X | ||||
| Total Debt | 145 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.07 X | ||||
| Book Value Per Share | 8.40 X | ||||
| Cash Flow From Operations | (106.3 M) | ||||
| Short Ratio | 10.08 X | ||||
| Earnings Per Share | (2.80) X | ||||
| Price To Earnings To Growth | 1.40 X | ||||
| Target Price | 25.27 | ||||
| Number Of Employees | 2.7 K | ||||
| Beta | 1.97 | ||||
| Market Capitalization | 2.1 B | ||||
| Total Asset | 1.2 B | ||||
| Retained Earnings | (366.2 M) | ||||
| Working Capital | 137.4 M | ||||
| Current Asset | 314.5 M | ||||
| Current Liabilities | 72.3 M | ||||
| Net Asset | 1.2 B |
About Myriad Genetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Myriad Genetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Myriad Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Myriad Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Myriad Genetics Piotroski F Score and Myriad Genetics Altman Z Score analysis. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.Note that the Myriad Genetics information on this page should be used as a complementary analysis to other Myriad Genetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Myriad Stock analysis
When running Myriad Genetics' price analysis, check to measure Myriad Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Myriad Genetics is operating at the current time. Most of Myriad Genetics' value examination focuses on studying past and present price action to predict the probability of Myriad Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Myriad Genetics' price. Additionally, you may evaluate how the addition of Myriad Genetics to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Is Myriad Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.80) | Revenue Per Share 9.114 | Quarterly Revenue Growth 0.116 | Return On Assets (0.07) | Return On Equity (0.29) |
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.